Category Archives: Cancer

Target-Selective Phototherapy Using a Ligand-Based Photosensitizer for Type 2 Cannabinoid Receptor.

Posted on by

“Phototherapy is a powerful, noninvasive approach for cancer treatment, with several agents currently in clinical use.

…we developed a phototherapy agent that combines a functional ligand and a near infrared phthalocyanine dye. Our target is type 2 cannabinoid receptor (CB2R), considered an attractive therapeutic target for phototherapy given it is overexpressed by many types of cancers that are located at a surface or can be reached by an endoscope.

Overall, this opens up the opportunity for development of an alternative treatment option for CB2R-positive cancers.”

http://www.ncbi.nlm.nih.gov/pubmed/24583052

Endocannabinoid system in cancer cachexia.

Posted on by

Image result for current opinion in clinical nutrition & metabolic care

“More than 60% of advanced cancer patients suffer from anorexia and cachexia.

This review focuses on the possible mechanisms by which the endocannabinoid system antagonizes cachexia-anorexia processes in cancer patients and how it can be tapped for therapeutic applications.

Cannabinoids stimulate appetite and food intake…

Cannabinoid type 1 receptor activation stimulates appetite and promotes lipogenesis and energy storage.

Further study of cancer-cachexia pathophysiology and the role of endocannabinoids will help us to develop cannabinoids without psychotropic properties, which will help cancer patients suffering from cachexia and improve outcomes of clinical antitumor therapy.”

http://www.ncbi.nlm.nih.gov/pubmed/17563462

The endocannabinoid signaling system in cancer.

Posted on by

Image result for trends in pharmacological sciences

“The endocannabinoid system, comprising lipid-derived endocannabinoids, their G-protein-coupled receptors (GPCRs), and the enzymes for their metabolism, is emerging as a promising therapeutic target in cancer.

This report highlights the main signaling pathways for the antitumor effects of the endocannabinoid system in cancer and its basic role in cancerpathogenesis, and discusses the alternative view of cannabinoid receptors as tumor promoters.

We focus on new players in the antitumor action of the endocannabinoid system and on emerging crosstalk among cannabinoid receptors and other membrane or nuclear receptors involved in cancer.”

http://www.ncbi.nlm.nih.gov/pubmed/23602129

Cannabinoid CB1 Receptor Is Downregulated in Clear Cell Renal Cell Carcinoma

Posted on by

“Several studies in cell cultures and in animal models have demonstrated that cannabinoids have important antitumoral properties… many of these effects are mediated through cannabinoid (CB) receptors CB1 and CB2…

The obtained data suggest a possible implication of the endocannabinoid system in renal carcinogenesis.”

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2989249/

 

 

Marijuana as a possible treatment for HIV and cancer

Posted on by

Marijuana

“There’s been some interesting research on using THC (tetrahydrocannabinol), the principal psychoactive drug in marijuana, to help fight HIV, and damage cancer cells in some leukemias and possibly malignant tumors.

…the possibility exists that information from both of these research studies may produce beneficial results in the treatment of HIV and cancer.”

More: http://americablog.com/2014/02/marijuana-treatment-hiv-cancer.html

Knocking down the expression of adenylate cyclase-associated protein 1 inhibits the proliferation and migration of breast cancer cells.

Posted on by

“Adenylate cyclase-associated protein 1 (CAP1) is a conserved protein that was found to be up-regulated in breast cancer and related to the migration of breast cancer…

CAP1 might be a potential molecular targeted therapy for surgery and immune treatment.”

http://www.ncbi.nlm.nih.gov/pubmed/24509166

Upregulated expression of CAP1 is associated with tumor migration and metastasis in hepatocellular carcinoma.

Posted on by

“Hepatocellular carcinoma (HCC) is one of the most common cancers that exhibits high incidences of intrahepatic metastasis and tumor recurrence.

Adenylate cyclase-associated protein 1 (CAP1)… was recently reported to play a role in cell motility and the pathology of pancreatic cancer. In this study, we examined a potential role of CAP1 in HCC progression, and found that CAP1 was overexpressed in HCC specimens…

Collectively, our results indicated that upregulated expression of CAP1 might contribute heavily to the metastasis of HCC.”

http://www.ncbi.nlm.nih.gov/pubmed/24359721

 http://www.thctotalhealthcare.com/category/hepatocellular-carcinoma-hcc/

Overexpression of adenylate cyclase-associated protein 1 is associated with metastasis of lung cancer.

Posted on by

“Lung cancer ranks first in both prevalence and mortality rates among all types of cancer. Metastasis is the main cause of treatment failure. Biomarkers are critical to early diagnosis and prediction and monitoring of progressive lesions…

The present study assessed the diagnostic and prognostic value of cyclase-associated protein 1 (CAP1) for lung cancer…

These findings suggest that overexpression of CAP1 in lung cancer cells, particularly at the metastatic stage, may have significant clinical implications as a diagnostic/prognostic factor for lung cancer.”

http://www.ncbi.nlm.nih.gov/pubmed/23842884

http://www.thctotalhealthcare.com/category/lung-cancer/

Adenylate cyclase-associated protein 1 overexpressed in pancreatic cancers is involved in cancer cell motility

Posted on by

“Pancreatic cancer is a leading cause of cancer death worldwide… Pancreatic cancer has the worst prognosis among cancers due to the difficulty of early diagnosis and its aggressive behavior.

…the adenylate cyclase-associated protein 1 (CAP1) gene was shown to be overexpressed in all of the xenografts.

Knockdown of CAP1 by RNA interference resulted in the reduction of lamellipodium formation, motility, and invasion of pancreatic cancer cells.

This is the first report demonstrating the overexpression of CAP1 in pancreatic cancers and suggesting the involvement of CAP1 in the aggressive behavior of pancreatic cancer cells.”

http://www.nature.com/labinvest/journal/v89/n4/full/labinvest20095a.html

http://www.thctotalhealthcare.com/category/pancreatic-cancer/

Inhibition of adenylate cyclase by delta 9-tetrahydrocannabinol in mouse spleen cells: a potential mechanism for cannabinoid-mediated immunosuppression.

Posted on by

“The ability of delta 9-Tetrahydrocannabinol (delta 9-THC) to modulate adenylate cyclase activity in mouse spleen cells was investigated…

delta 9-THC treated spleen cells demonstrated a 33% inhibition and a 66% inhibition in intracellular cAMP… respectively…

These studies suggest that inhibition of immune function by delta 9-THC may be mediated through the inhibition of intracellular cAMP early after antigen stimulation.”

http://www.ncbi.nlm.nih.gov/pubmed/1321935